resum coverag buy pt
messag resum coverag buy rate pt
poziotinib tyrosin kinas inhibitor tki late stage develop treatment
patient nsclc exon egfr mutat respect top-
line result guid rolonti novel long-act g-csf manag
chemotherapy-induc neutropenia bla re-submiss guid year potenti
posit pivot trial result pozioniotnib exon egfr nsclc repres
potenti catalyst stock view posit read-though potenti
develop indic
rate buy pt follow recent divestitur
commerci pipelin clinical-stag focus develop
 commerci poziotinib pozi tki address exon egfr
rolonti long-act g-csf granulocyte-coloni stimul factor
develop manag chemotherapy-induc neutropenia pozi potenti
address high unmet need exon posit egfr non-smal cell lung cancer
nsclc patient occur patient resist standard care egfr
inhibitor tagrisso azn lack approv target therapi drug also
potenti nsclc patient exon mutat pozi potenti
tumor repres sourc upsid valuat current includ
revenu potenti beyond nsclc given limit line-of-sight data date rolonti
estim reflect conserv view revenu potenti given non-inferior
neulasta avail multipl neulasta biosimilar assum modest
uptak g-csf market pend fda approv pt consist
poziotinib pos-adjust rolonti pos-adjust estim
cash year bull-cas scenario model suggest hypothet valuat
year assum favor pozi readout exon nsclc guidanc
combin disappoint result competitor exon egfr inhibitor
success bla re-fil rolonti think stock could hypothet trade
bear-cas scenario year poziotinib pivot trial result exon nsclc disappoint
and/or competitor exon data look compel rolonti bla re-submiss
forecast us probability-adjust poziotinib revenu account
per share valuat current model success probabl
pozi egfr egfr
nsclc respect assum indic launch time
respect posit newsflow poziotinib combin trial expect compani
start tumor type may repres potenti upsid current
pozi potenti address unmet need within egfr exon nsclc exon
egfr mutat constitut nsclc remain unmet need given resist
current approv egfr inhibitor associ poorer outcom earli data
present world confer lung cancer wclc suggest pozi potenc
confirm respons rate orr evalu egfr
exon patient respect compar favor view tagrisso
orr similar set opdivo cyramza orr
all-com nsclc popul potenti investor controversi pozi clinic profil
includ toler concern given high incid grade rash diarrhea
rash diarrhea gbcc wclc respect rel
egfr tki nsclc
clear first-mov advantag egfr exon nsclc exon
tumor may becom competit takeda tak exon inhibitor
previous read initi phase dose escal data report
orr confirm evalu patient treat least mg dose
page analyst certif import disclosur
phase trial expect updat dose escal data oral abstract
see preview note tak guid initi pivot phase ii exon
nsclc potenti exon inhibitor includ tarloxotinib
undergo phase ii trial preclin cullinan oncolog taiho
front dsnki read earli nsclc
data includ orr patient exon mutat pyrotinib peke
union medic colleg read phase ii data exon nsclc poster
abstract see preview note
rolonti estim assum moder penetr chemo-induc
neutropenia contribut share valuat less reflect stock
follow bla withdraw view although rolonti differenti
pegyl g-csf product includ standard care neulasta two separ phase trial
abl demonstr non-inferior efficaci similar safeti profil
market leader addit long-act g-csf market multipl avail emerg
biosimilar udencya fluphila nv
model peak market share rolonti assum launch result
peak us peak row probability-adjust sale po modest
forecast rolonti sale account per share valuat repres half
earli clinical-stag asset in-licens april repres
potenti long-term upsid valuat in-licens two antibody-
interferon fusion molecul well
exclus licens use antibody-interferon fusion drug deliveri platform anti-
asset phase dose escal r/r non-hodgkin lymphoma includ diffus
larg b-cell lymphoma dlbcl remain preclin develop
similar prior licens agreement hanmi md anderson
contractu oblig pay regulatori sale mileston addit royalti net
upcom potenti stock catalyst pipelin event expect updat result
support potenti acceler approv egfr exon nsclc around
time cohort evalu exon nsclc patient
complet enrol provid guidanc specif time around bla
re-submiss rolonti current assum base case
page analyst certif import disclosur
valuat risk
valu per share use discount cash flow analysi
use wacc consist clinical-stag biotech compani
cover proof-of-concept data well termin growth rate consist
smidcap biotech name coverag
risk includ regulatori commerci setback potenti emerg new
competitor lower product sale expect dilut financ beyond
assum
page analyst certif import disclosur
servic revenu
amort intang asset
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
